BNET Industries
Market Cap:$149.2B
Last Fiscal Year Sales:$48.4B
- Public
- US
Dow Jones Description
Taking care of you and your four-legged friends too! Pfizer Inc. (NYSE: PFE), based in New York, NY, discovers, develops, manufactures and sells prescription medications for humans and animals. Employing about 115,000 people, this $51.3 billion company operates in three segments: Human Health, Consumer Healthcare and Animal Health. Together, these segments cover treatments for diseases such as cardiovascular and metabolic diseases, medications for oral care, tobacco dependence, and products for prevention and treatment of diseases in livestock and pets.
Number of Employees 81,800
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Bristol-Myers Squibb Raises Exchange Offer Price For Mead Johnson Shares - Update
-
'IT boosts efficiency & innovation'
-
Inspector General Saved Billions in Healthcare This Year
-
Pfizer and B.C. launch $9M collaboration to tackle cancer
-
Reportlinker Adds Growth Factors Blood And Tissue - A World Report
-
Pfizer signs agreement with Protalix BioTherapeutics for Taliglucerase alfa
-
Pfizer Inc. PFE JOBS Acquires Rights to Protalix Biotherapeutics's Gaucher Drug in Deal Worth $115M
-
Roche's Merger Formula for Genentech
-
Pfizer PFE Will Not Renew Ethical Distribution Agreement Term with MWI Veterinary Supply MWIV
-
Pfizer Inc. and Wyeth; Analysis of Agreement Containing Consent Order To Aid Public Comment and...
-
A 2nd Loss for Pfizer in Drug Suits
-
Pfizer acquires stem cell therapies assets of Axordia
-
Standpoint Raised Its FY10 Price Target on Pfizer PFE to $24
-
ImmunoVaccine signs exclusive licence deal with Pfizer
-
Pfizer Animal Health selects Bader Rutter as agency of record
-
FDA panel backs Pfizer's anti-infection vaccine for kids
-
Cash Just Kept On Piling Up, But It Looks Like The Spending Has Started
-
Goldman Sachs Said Pfizer PFE Best Positioned US Pharma in China
News & Analysis
Filter by
health care and pfizer inc. and pharmaceutical company - All News and Analysis
Starved of News, Press Speculates on Deals for Abbott, Pfizer and Wyeth
BNET
- 2009-01-05
New Year is a slow news period, which is why the business press filled up with next-to-useless corporate strategy stories about Abbott Labs, Wyeth and Pfizer. The one thing these stories all have in common? They're long on speculation and short on substance. Let's take them one at a time....
Good Medicine.(Biotech industry.)
- 2005-05-10
Byline: Steven Goldberg, Kiplinger Washington Editors Biotech is beginning to realize its potential -- for investors as well as patients. Meanwhile, pharmaceutical companies are continuing to struggle, although they will probably begin to see Byline: Steven Goldberg, Kiplinger...
Pharmaceutical profits and the discovery of new medicines. (Pfizer forum).(adapted from Health Affairs, September/October 2001)(Brief Article)
- 2002-06-01
Since the late 1950s, when the Kefauver Committee investigated the business practices of U.S. pharmaceutical companies, representatives of that sector have argued that its profits are an important stimulus to, and source of funding for, research and Since the late 1950s, when the Kefauver Committee...
Pfizer writes its own prescription for growth;Drug company expands via R&D, sales efforts; reaches crossroads as megamerger approaches.
- 2000-05-15
when hillary rodham clinton set out to reform the health care system in 1993, pharmaceutical companies, fearful that price controls were on the horizon, ran for cover, spending billions to diversify into new lines of business. The march of managed ca when hillary rodham clinton set...
CHANGING CLIMATE: UNCERTAINTY COOLS INTEREST IN DRUG COMPANY STOCKS; POLITICS, LACK OF NEW MEDICINES HAS SOME WARY.
- 1999-03-08
Meddling by President Clinton and a lack of blockbuster drugs in the pipeline raise red flags for institutional managers investing in the drug industry. Large-cap pharmaceutical companies such as Pfizer Inc. and Merck & Co. Inc. have been popu Meddling by President Clinton...
To Your Health.(pharmaceutical industry marketing)
- 1998-09-07
00-00-0000 Reaping the benefits of new drug discovery, pharmaceutical companies are now flexing their marketing muscle. IN A RECENT SURVEY OF PHYSICIANS, 29% SAID THEY RECEIVED specific requests from patients for Schering- Plough Corp.'s Claritin, ma 00-00-0000 Reaping the benefits of new drug discovery,...
- 1
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
